戻る Agenda
Session 8: Patient Access
Session Chair(s)
Michael Muenzberg
Vice President, Director Medical Affairs Biosimilars
Ares Trading S.A, Switzerland
Biologic medicines play an increasing role in the patient care across a growing number of disease areas. Access to these modern therapies remains restricted due to the high cost of these medicines. This session will look at the current barriers to accessing existing biologic therapies and how the emergence of biosimilar medicines across Europe and in the US brings the promise to overcome those, offering opportunities for health systems to expand access for more patients, but also foster investment in new areas of care while providing relief on health care budgets.
Speaker(s)
Increasing Information for Patients About Accessing Treatments Biosimilars and Clinical Trials
Paulo Moreira
Agenus, United States
Global Head of Clinical Operations
An Overview of Current Biosimilars Reimbursement Practive and Medicare
John Carlsen, MHA
Covance Market Access Services Inc., United States
Vice President
AARP’s Perspective on Access to Biologic Medicines
Leigh Purvis, MPA
American Association of Retired Persons (AARP), United States
Director, Health Services Research
Panel Discussion
All Session Speakers, United States